Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators

Table 2

Unadjusted and adjusted hazard ratios for all-cause mortality following PSA failure.

Clinical  factor	Number of men	Number of events	Univariable HR  (95% CI)	𝑃	Multivariable; AHR (95% CI)	𝑃
Treatment arm
Radiation	35	16	Ref.	—	Ref.	—
Radiation + ADT	18	8	1.01 (0.43–2.37)	0.99	1.69 (0.68–4.19)	0.26
Gleason
≤7	45	18	Ref.	—	Ref.	—
>7	8	6	2.02 (0.80–5.10)	0.14	0.82 (0.28–2.44)	0.72
Clinical T category
T1	23	10	Ref.	—	Ref.	—
T2	30	14	0.93 (0.41–2.13)	0.87	0.65 (0.25–1.72)	0.39
ACE-27 comorbidity
None or minimal	41	14	Ref.	—	Ref.	—
Moderate or severe	12	10	5.32 (2.31–12.3)	<0.001	12.50 (3.81–41.0)	<0.001
Age in years at PSA failure	53	24	1.12 (1.02–1.22)	0.01	1.14 (1.03–1.25)	0.008
Interval to PSA failure in months*	53	24	1.73 (0.75–3.98)	0.20	2.36 (0.89–6.26)	0.09
PSA doubling time in months*	53	24	0.98 (0.60–1.59)	0.92	1.15 (0.63–2.08)	0.66

∗Log-transformed.
ADT: androgen deprivation therapy; PSA: prostate specific antigen.